Form 4: Alnylam Director Trades Under 10b5-1 Plan

Alnylam Pharmaceuticals Director David E.I. Pyott executed a series of stock transactions under a pre-arranged Rule 10b5-1(c) trading plan.

Summary

• Director David E.I. Pyott of Alnylam Pharmaceuticals, Inc. (ALNY) engaged in stock transactions on June 1, 2026.
• These transactions were conducted under a Rule 10b5-1(c) trading plan adopted on November 12, 2025.
• Pyott exercised stock options and sold common stock.
• Specifically, 3,830 shares were acquired via option exercise at $0 cost.
• Following the exercise, 921 shares were sold at a weighted average price of $297.71, 1,175 shares at $298.91, 1,222 shares at $299.87, and 495 shares at $300.72.
• An additional 17 shares were sold at $302.65.
• The total number of common stock shares beneficially owned by Pyott after these transactions is 1,582 shares directly, and 27,900 shares indirectly held by a trust where he is trustee.
• The stock options exercised were set to expire on June 3, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While it involves significant stock sales by a director, the transactions were conducted under a pre-established Rule 10b5-1 plan and coincided with option expiration, mitigating concerns about negative insider sentiment.

Positives

• Transactions were executed under a Rule 10b5-1(c) plan, indicating pre-planned and potentially less market-impactful trading.
• Director Pyott continues to hold a significant number of shares (1,582 direct, 27,900 indirect) after the transactions.
• The exercise of options and subsequent sales occurred at prices generally above the exercise price, suggesting a profitable outcome for the exercised options.

Negatives

• Director Pyott sold a substantial number of shares (3,830 shares from option exercise and subsequent sales totaling 2,608 shares), which could be perceived negatively by the market.
• The weighted average sale prices indicate a gradual sale of shares, potentially to minimize market impact but also showing a consistent divestment.

Risks

• The sale of shares by a director, even under a 10b5-1 plan, can sometimes be interpreted by the market as a lack of confidence in future stock performance.
• The options exercised were nearing their expiration date (June 3, 2026), suggesting a need to realize value before expiry.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance from the company. The future outlook for the stock would depend on Alnylam Pharmaceuticals' overall business performance and market conditions, not directly on this insider transaction report.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those under Rule 10b5-1 plans, are common for executives and directors to manage their personal portfolios. The timing of these sales, coinciding with option expiration, is a typical strategy to monetize vested equity. Alnylam Pharmaceuticals operates in the competitive biotechnology sector, where such transactions are closely watched by investors.

Stakeholder Impact

• Shareholders: May interpret the sale of shares by a director as a potential negative signal, although the Rule 10b5-1 plan and option expiration context may temper this view.
• Employees: Similar to shareholders, employees may observe insider selling, but the pre-planned nature of the trade is a mitigating factor.
• Creditors/Suppliers: Unlikely to be directly impacted by this specific insider transaction report.

Next Steps

• The reporting person will provide further details on sale prices upon request from the issuer, security holders, or the SEC.
• The stock options exercised were due to expire on June 3, 2026, indicating a realization of value before expiry.

Key Dates

Keywords

Form 4, SEC Filing, Alnylam Pharmaceuticals, ALNY, David E.I. Pyott, Director, Stock Options, Rule 10b5-1, Insider Trading, Beneficial Ownership, Stock Sales, Stock Exercise